✦ LIBER ✦

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

✍ Scribed by Gaudet, D; Méthot, J; Déry, S; Brisson, D; Essiembre, C; Tremblay, G; Tremblay, K; de Wal, J; Twisk, J; van den Bulk, N; Sier-Ferreira, V; van Deventer, S

Book ID: 111943859
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 613 KB
Volume: 20
Category: Article
ISSN: 0969-7128
DOI: 10.1038/gt.2012.43

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pancreatitis in patients with lipoprotei

Pancreatitis in patients with lipoprotein lipase deficiency and the effect of alipogene tiparvovec (AAV1-LPLS447X gene therapy)

✍ Deakin, M.; De Wal, J.; Camozzi, C.; Bruno, M.; Ruszniewski, P.; Gaudet, D. 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 48 KB

Abstract: 554 AN OPEN-LABEL, DOSE ESCALA

Abstract: 554 AN OPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND EFFICACY OF AAV1-LPLS447X GENE THERAPY WITH ALIPOGENE TIPARVOVEC (AMT-011) FOR PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA DUE TO LIPOPROTEIN LIPASE DEFICIENCY (LPLD)

✍ Gaudet, D; Brisson, D; Methot, J; van Deventer, S 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 76 KB